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A B S T R A C T
Cattle trypanosomosis caused by Trypanosoma vivax is a widely distributed disease in Africa and Latin America. It
causes signiﬁcant losses in the livestock industry and is characterized by ﬂuctuating parasitemia, anemia, fever,
lethargy, and weight loss. In this study we evaluated the virulence (capacity to multiply inside the host and to
modulate the host response) and pathogenicity (ability to produce disease and/or mortality) patterns of two T.
vivax strains (TvMT1 and TvLIEM176) in experimentally-infected sheep and determined the proteins diﬀeren-
tially expressed in the proteomes of these two strains. Hematological and clinical parameters were monitored in
experimentally-infected versus non-infected sheep for 60 days. All the infected animals developed discernable
parasitemia at 3 days post-infection (dpi), and the ﬁrst parasitemia peak was observed at 6 dpi. The maximum
average value of parasitemia was 1.3 × 107 (95% CI, 7.9 × 105–2 × 108) parasites/ml in TvLIEM176-infected
animals, and 2.5 × 106 (95% CI, 1.6 × 105–4 × 107) parasites/ml in TvMT1-infected ones. Anemia and clinical
manifestations were more severe in the animals infected by TvMT1 strain than in those infected by TvLIEM176.
In the proteomic analysis, a total of 29 proteins were identiﬁed, of which 14 exhibited signiﬁcant diﬀerences in
their expression levels between strains. Proteins with higher expression in TvLIEM176 were: alpha tubulin, beta
tubulin, arginine kinase, glucose-regulated protein 78, paraﬂagellar protein 3, and T-complex protein 1 subunit
theta. Proteins with higher expression in TvMT1 were: chaperonin HSP60, T-complex protein 1 subunit alpha,
heat shock protein 70, pyruvate kinase, glycerol kinase, inosine-5'-monophosphate dehydrogenase, 73 kDa
paraﬂagellar rod protein, and vacuolar ATP synthase. There was a diﬀerence in the virulence and pathogenicity
between the T. vivax strains: TvLIEM176 showed high virulence and moderate pathogenicity, whereas TvMT1
showed low virulence and high pathogenicity. The proteins identiﬁed in this study are discussed for their po-
tential involvement in strains’ virulence and pathogenicity, to be further deﬁned as biomarkers of severity in T.
vivax infections.
1. Introduction
Cattle trypanosomosis, a very important livestock disease, is caused
by Trypanosoma congolense, T. brucei and T. vivax in Africa (Auty et al.,
2015; Chamond et al., 2010). In Latin America, bovine trypanosomosis
is caused by T. vivax and T. evansi, which are mechanically transmitted
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by blood-sucking insects (Desquesnes, 2004; Ramírez-Iglesias et al.,
2017). This disease is characterized by ﬂuctuating parasitemia, fever,
anemia, lethargy, loss of weight, decrease in milk production, re-
productive failures and, eventually, death, causing signiﬁcative losses
in the livestock industry. Epidemiological studies in Venezuela have
shown serological prevalence values, determined by ELISA, between
20.8 to 33.1% for T. vivax (Suárez et al., 2009; Toro et al., 1980).
It has been proposed that the severity of the disease depends on
parasite strain, endemicity and host species (Auty et al., 2015; Batista
et al., 2007; Morrison et al., 2016). However, the discrete roles the host,
the parasite, and their relationships at the molecular level play in the
diﬀerent clinical disease presentations are poorly understood. The ex-
ploration of host-parasite interactions could lead to the development of
improved diagnostic tools, new drugs, and/or vaccine strategies.
Vaccine control of trypanosomosis is strongly limited by the com-
plexity of the parasite’s antigenic repertoire. A further challenge is that
knowledge about trypanosome antigenic variation comes primarily
from the T. brucei model where variant surface glycoprotein (VSG) is
highly immunogenic. T. vivax expression of the VSG repertoire diﬀers
from that of T. brucei, and this protein family is not the most im-
munodominant antigen in this species (Fleming et al., 2016; Greif et al.,
2013; Jackson et al., 2012; Ramirez-Barrios et al., 2015). The identiﬁ-
cation of invariant trypanosome components rather than variant sur-
face proteins as potential targets for limiting infection or infection-
mediated disease has been the focus of some previous studies (Black
and Mansﬁeld, 2016; Grébaut et al., 2009); thus, characterization of
pathogenic or virulent biomarkers is highly relevant.
The extracellular localization of these trypanosome species within
their mammalian hosts results in extensive molecular interactions with
this environment. Previous studies of T. vivax in diﬀerent hosts have
demonstrated that parasite and host genotypes have a major impact on
infection progression (de Gee et al., 1979, 1981, 1982). Diﬀerences
have been found in the susceptibility of inbred mouse strains to infec-
tions with T. vivax isolates of medium or low virulence; however, no
resistant model has been identiﬁed (de Gee et al., 1982). Although
mouse models have been useful to understand the course and disease
progression in T. vivax-infected animals (Blom-Potar et al., 2010;
Chamond et al., 2010), the use of natural hosts (ruminants) will result
in more eﬃcient development of relevant and eﬀective tools to combat
this infectious disease.
The outcome of host-parasite interaction is determined by the
nature of the damage that results from the molecular battle. Disease
occurs when the host sustains suﬃcient damage to perturb homeostasis.
Historically, pathogenicity and virulence have been diﬃcult to deﬁne.
In this study, pathogenicity is deﬁned as the ability of a microorganism
to produce disease and/or mortality (Devera et al., 2003; Pirofski and
Casadevall, 2012). Moreover, virulence is a relative term and, ac-
cording to modern deﬁnitions, is the ability of a pathogen to multiply
inside a susceptible host and to modulate the host response (Devera
et al., 2003; Holzmuller et al., 2008). Therefore, this means that viru-
lence is a dependent variable that is contingent on the availability of a
susceptible host and should be studied within the context of the host-
pathogen interaction (Casadevall and Pirofski, 2001).
The aims of this study were to evaluate the virulence and patho-
genicity of two T. vivax strains in experimentally-infected sheep, and
identify the diﬀerentially expressed proteins between them with a
combination of 2-D diﬀerential in-gel electrophoresis (DIGE) and mass
spectrometry (MS).
2. Materials and methods
2.1. Parasites
The strains used in the experiments, TvLIEM176 (a gift from Dr.
Laura Moron and Dr. Glenda Moreno, Los Andes University) and
TvMT1, were obtained from naturally-infected cattle from diﬀerent
locations in Venezuela: TvLIEM176 from Trujillo State (Western region)
and TvMT1 from Monagas State (Eastern region) as previously de-
scribed (Gómez-Piñeres et al., 2014). Diagnosis of infection was per-
formed by microhematocrit analysis (Woo, 1969) and polymerase chain
reaction (PCR) as described (Masake et al., 1997). Blood was collected
in tubes containing 1 mg/ml of ethylenediaminetetracetic acid (EDTA),
mixed with 10% glycerol in 20 mM phosphate buﬀered saline (PBS) pH
7.2 containing 1% glucose (PBSG) and frozen in liquid nitrogen
(Gómez-Piñeres et al., 2009; Ndao et al., 2004).
2.2. Experimental infections
Nine adult Barbados Blackbelly sheep, eighteen months old,
weighing 20 kg, and negative for T. vivax infection (determined by
ELISA and PCR tests) were purchased from a local market. Tests for
gastrointestinal parasites (fecal ﬂotation test) and liver ﬂuke (fecal se-
dimentation test) were performed at time of purchase. Three animals
were positive for gastrointestinal nematodes. Ivermectin at a dose of
0.2 mg/kg was administered to all animals. Two weeks before and
during experimental infection, all animals were maintained under ve-
terinary supervision in order to monitor animal health and welfare at
Centro Experimental de Producción Animal (CEPA, College of
Veterinary Medicine, University of Zulia) in ﬂy-proof pens. Three sheep
were inoculated intravenously with each isolate (106 parasites/animal)
and three were used as control. After 60-day infection period, the an-
imals were treated with diminazene aceturate (3.5 mg/kg). Clinical and
hematological tests were performed on a weekly base during 4 addi-
tional weeks in order to ensure that they were cured. Protocols used in
this study were approved by the University of Zulia Scientiﬁc
Committee (protocol CC-0497-12) according to the code for animal
experimentation and based on Venezuelan law (MCT-FONACIT, 2002).
2.3. Determination of virulence and pathogenicity patterns
In order to determine the virulence pattern of each isolate, parasite
presence in blood was determined by the microhematocrit centrifuge
technique (Woo, 1969) and then, parasitemia was measured every three
days during the complete infection period by the hemocytometer
method (Valera et al., 2005). Every three days, pathogenicity of each
isolate was evaluated by clinical and hematological evaluations in each
animal as follows:
2.3.1. Animals were examined for clinical signs of trypanosomosis
by collection and analysis of the following parameters: rectal tem-
perature (ºC), heart and respiration rates, color of the mucous mem-
branes, size of palpable lymph nodes, hydration status, body condition,
response to external stimuli, posture, coat condition, presence of la-
crimation, subcutaneous edema, and general attitude.
2.3.2. Blood samples were collected from the jugular vein using
vacutainer® tubes with EDTA as anticoagulant. Packed cell volume
(PCV) levels were measured as an estimation of anemia using capillary
microhematocrit centrifugation, and hemoglobin was determined
spectrophotometrically by the cyanmethemoglobin method (Jain,
1986). White blood cells (WBC) counts by the hemocytometer method
and leukocyte proﬁles were collected as described (Jain, 1986).
2.4. Statistical analysis
Linear mixed eﬀects models were built to estimate the eﬀect of the
treatment (inoculation with TvLIEM176 strain, inoculation with TvMT1
strain, non-infected control group), day (categorical with 21 levels: 0 to
60 dpi), and their interaction on the diﬀerent outcome variables: PCV,
hemoglobin, WBC, lymphocytes, neutrophils, monocytes, eosinophils,
parasitemia, body temperature, heart rate, and respiratory rate, with
sheep as the random intercept. In the models for WBC, lymphocytes,
neutrophils, monocytes, and eosinophils, a random coeﬃcient for day
(deviation of the sheep-speciﬁc coeﬃcient of day from the average
R. Ramirez-Barrios, et al. Veterinary Parasitology: X 2 (2019) 100014
2
coeﬃcient of day) was included. Examples of the linear mixed models
can be found in the supplemental material (supplementary statistical
information). Parasitemia values were log10-transformed, and the con-
trol group (non-infected) was not included in this particular analysis
since control sheep had no parasitemia during the study. REML was
used as the estimation method, and Kenward-Roger method was used to
calculate the degrees of freedom. Adjusted means are reported with
95% conﬁdence intervals (95% CI). Pairwise comparisons at each day
(corrected for multiple comparisons using Sidak’s method) as well as
overall treatment eﬀect (F test including both simple eﬀects and in-
teractions) were performed. Signiﬁcance level was set a priori at 0.05.
All statistical analyses were performed with Stata 15.1 software
(StataCorp, USA).
2.5. Protein puriﬁcation
An additional four sheep meeting the criteria in Section 2.2 “Ex-
perimental Infections” were purchased for acquisition of T. vivax for
proteomic analysis. Two sheep were infected with each isolate; how-
ever, only one animal developed parasitemia with TvMT1 isolate,
whereas the two were parasitized with TvLIEM176 isolate. The para-
sitized sheep and samples derived from them were henceforth identiﬁed
with “TvMT1”, “LIEM 1” and “LIEM 2” labels, respectively. Trypano-
somes were puriﬁed from infected animals when parasitemia reached
values of 2 × 107 parasites/ml or higher, according to the protocol
previously described (González et al., 2005). Subsequently, the parasite
membranes were disrupted by 4 cycles of freezing in liquid nitrogen
and thawing at room temperature, and the parasite homogenate was
centrifuged to recover the soluble protein fraction (supernatant). Later,
the samples were subjected to precipitation with 2-D Clean-Up Kit (GE
Healthcare Life Sciences) according to the manufacturer’s protocol.
Protein from a sample of pre-obtained Venezuelan T. evansi isolate,
TeAp-ElFrio01 (Perrone et al., 2009; Sánchez et al., 2015), was also
precipitated to be utilized in subsequent proteomic comparisons. The
resulting pellet from each sample was lyophilized and stored at−20 °C.
2.6. Preparation of protein samples and DIGE labelling
In preparation for 2D-DIGE/LC-MS/MS, lyophilized protein samples
were rehydrated in 50 μl of solubilization buﬀer (7 M urea, 2 M
thiourea, 4% w/v CHAPS, 30 mM Tris, 0.5% Triton X-100) and
cOmplete™ Protease Inhibitor Cocktail (Roche) overnight at room
temperature. The total protein concentration of each sample was de-
termined by Bradford assay (Bradford, 1976).
For 2D-DIGE separation, proteins were labeled according to the
manufacturer’s instructions (GE Healthcare). For each sample (TvMT1,
LIEM 1, LIEM 2, and T. evansi), 50 μg of protein was labelled with
400 pmol of Cy3 ﬂuorochrome and, as a separate technical replicate,
with Cy5 ﬂuorochrome (CyDyesPM, GE Healthcare) for 30 min on ice in
the dark. This dye swap labelling of technical replicates eliminated
speciﬁc dye eﬀects from the subsequent pairwise comparisons in four
gels represented in Table S1. An internal standard, containing equal
amounts of each protein extract, was labelled with Cy2 ﬂuorescent dye,
and used in all gel comparison experiments to normalize protein levels
across gels and to control gel-to-gel variation (Alban et al., 2003).
2.7. Two-dimensional gel electrophoresis
The Cy2 standard, one sample labelled with Cy3 and another sample
labelled with Cy5 were mixed (150 μg total protein) in a rehydration
solution (7 M Urea, 2 M thiourea, 4% CHAPS, 0.5% Triton X-100,
12 μl/ml Destreak Reagent (GE Healthcare) and 1% immobilized pH
gradient (IPG) buﬀer, pH 3–10). The proteins were separated in the ﬁrst
dimension within 24 cm immobilized pH gradient strips, pH 3–10, non-
linear (NL) (GE Healthcare), which were passively rehydrated for 14 h.
Isoelectric focusing was performed using an Ettan IPGphor system 3
(GE Healthcare) as follows: 3 h at 60 V, 4 h gradient to 1000 V, 4 h
gradient to 8000 V and 8000 V constant to reach a total of 80,000 V h.
After isoelectric focusing, strips were incubated in equilibration solu-
tion (6 M urea, 300 mM Tris pH 8.8, 0.2% SDS, 30% glycerol, 1% DTT)
for 15 min, followed by a second 15 min incubation step with the same
equilibration buﬀer in which DTT was replaced by 2.5% iodoaceta-
mide. The equilibrated IPG strips were positioned on top of an SDS-
polyacrylamide gel (12% acrylamide, resolution 10–100 kDa) and
sealed with 1% agarose for second dimension separation. The electro-
phoresis was performed using an Ettan Dalt Twelve gel caster system
(GE Healthcare) at 17 °C and 17 mA/gel.
2.8. Image analysis and statistics
The gels were scanned and visualized using a Typhoon 9400 (GE
Healthcare) using appropriate wavelengths and ﬁlters for Cy2: 490 nm,
Cy3: 550 nm, and Cy5: 650 nm. Spot detection and quantiﬁcation were
performed with Progenesis SameSpots v3.0 software (Nonlinear
Dynamics Ltd.). Spot quantitation was normalized using a Cy2-labelled
internal standard. The volume of each spot was calculated as the pro-
duct of spot area and spot intensity. Diﬀerential expression analysis was
performed by comparing matched spots volumes between the T. vivax
isolates. Protein expression of T. evansi was used as an exclusion ﬁlter.
To select relevant spots, the one-way ANOVA test (P-value≤0.05 and a
fold change ≥2) provided in the SameSpots software (Table S2) was
used.
2.9. Protein gel excision and digestion
Gels were stained using Coomassie Brilliant Blue and the spots of
interest were manually excised from each gel in a laminar ﬂow hood.
Proteins were in-gel digested with trypsin as previously described
(Wilm et al., 1996).
2.10. Nano LC-MS/MS and protein identiﬁcation
Peptide samples were dehydrated in a vacuum centrifuge and then
solubilized in 5 μl of 0.1% formic acid/2% acetonitrile. Three (3) μl
were analyzed online by nano-ﬂow HPLC-nanoelectrospray ionization
using an LTQ Orbitrap XL mass spectrometer (LTQ Orbitrap XL, Thermo
Fisher Scientiﬁc, San Jose, CA) coupled with an Ultimate 3000 HPLC
(Dionex). Desalting and pre-concentration of samples were performed
on-line on a Pepmap® precolumn (0.3 mm x 10 mm). A gradient con-
sisting of 0–40 % A in 30 min, 80 % B in 15 min (A = 0.1 % formic
acid, 2 % acetonitrile in water; B = 0.1 % formic acid in acetonitrile)
at 300 nl/min was used to elute peptides from the capillary
(0.075 mm x 150 mm) reverse-phase column (Pepmap®, Dionex). LC-
MS/MS experiments comprised cycles of 5 events: an MS1 scan with
orbitrap mass analysis at 60,000 resolution followed by collision-in-
duced dissociation (CID) of the ﬁve most abundant precursors.
Fragment ions generated by CID were detected at the linear trap.
Normalized collision energy of 35 eV and activation time of 30 ms were
used for CID. All spectra were recorded under positive ion mode using
the Xcalibur 2.0.7 software (Thermo Fisher Scientiﬁc) with the instru-
ment operating in the information-dependent acquisition mode
throughout the HPLC gradient. The mass scanning range was m/z
400–2000 and standard mass spectrometric conditions for all experi-
ments were: spray voltage, 2.2 kV; no sheath and auxiliary gas ﬂow;
heated capillary temperature, 200 °C; capillary voltage, 40 V and tube
lens, 120 V. For all full scan measurements with the Orbitrap detector a
lock-mass ion from ambient air (m/z 445.120024) was used as an in-
ternal calibrant as described (Olsen et al., 2005).
All MS/MS spectra were searched against the Trypanosoma entries
of either SwissProt or TrEMBL databases (http://www.uniprot.org/; v
2012_07) by using the Proteome Discover software v 1.3 (Thermo
Fisher Scientiﬁc) and Mascot v 2.3 algorithm (http://www.
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matrixscience.com/) with trypsin enzyme speciﬁcity and one trypsin
missed cleavage. Carbamidomethylation was set as ﬁxed cysteine
modiﬁcation and oxidation was set as variable methionine modiﬁcation
for searches. A peptide mass tolerance of 5 ppm and a fragment mass
tolerance of 0.5 Da were allowed for identiﬁcation.
Management and validation of mass spectrometry data were carried
out using Proteome Discoverer software v 1.3 (P < 0.01 for 2 peptides
or more/protein). The mass spectrometry proteomics data have been
deposited to the ProteomeXchange Consortium via the PRIDE (Perez-
Riverol et al., 2019) partner repository with the dataset identiﬁer
PXD013266.
2.11. Bioinformatics analysis
Diﬀerentially expressed peptides between strains were utilized to
search the T. vivax transcriptome database (http://bioinformatica.fcien.
edu.uy/Tvivax/) for the amino acid sequence of each full-length T.
vivax protein (Greif et al., 2013). This database was generated from the
TvLIEM176 strain used in this study.
3. Results
3.1. T. vivax strains TvMT1 and TvLIEM176 show diﬀerent virulence and
pathogenicity patterns
The host-pathogen interactions in animal trypanosomosis must be
analyzed from the parasite and the host perspectives; as host damage is
induced by both the parasite and the host’s own immune response.
Here, parasitemia levels as well as clinical and hematological ob-
servations associated with experimental infections of two T. vivax iso-
lates in sheep were evaluated.
Three (all) TvLIEM176- and two TvMT1-infected animals developed
parasitemia at 3 dpi, but the ﬁrst peak in levels of blood parasitemia
was observed at 6 dpi (Fig. S1, Table S3). The maximum average of
parasitemia reached in the ﬁrst peak (6 dpi) was 1.3 × 107 (95% CI,
7.9 × 105 – 2 × 108) parasites per ml of blood in TvLIEM176-infected
animals and 2.5 × 106 (95% CI, 1.6 × 105 – 4 × 107) parasites per ml
of blood in TvMT1-infected animals (Figs. 1A, S1). Then, parasitemia
ﬂuctuated for the rest of the trial period. Although parasitemia values
were higher in TvLIEM176 infected animals than in TvMT1 ones during
the infection period, statistical diﬀerences (P < 0.05) were observed
only on 15 (P = 0.01), 27 (P = 0.009), 36 (P = 0.007), 42 (P = 0.022)
and 54 (P = 0.002) dpi (Fig. 1A, Table S3).
Anemia was important in the infected animals during the experi-
ment. PCV and hemoglobin showed similar curves with a decrease in
the values during the experimental period (Fig. 1B, 1C). The mean re-
duction of PCV and hemoglobin was higher in the animals infected with
the TvMT1 strain (47.3% and 43.6%, respectively) than in the group
infected with TvLIEM176 strain (25.3% and 25.4%, respectively). Both
infected groups showed signiﬁcant statistical diﬀerences in PCV values
between them (P < 0.001) and when compared with the control group
(P < 0.001) (Fig. 1B), except on 15 dpi. After 6 dpi, hemoglobin va-
lues were statistical diﬀerent (P < 0.001) between both infected
groups, being lower in TvMT1-infected animals (Fig. 1C). Taken to-
gether, these alterations indicate that TvMT1 isolate was capable of
producing more severe anemia than TvLIEM176 isolate.
WBC (Fig. 1D) count was reduced in both infected groups (TvMT1
and TvLIEM176) and reached values very close to the normal lower
limit for sheep. There were signiﬁcant statistical diﬀerences in the va-
lues of both infected groups when compared with the control group
from 15 dpi until the end of the experimental period (P < 0.001).
There was a statistically signiﬁcant diﬀerence between the WBC values
of infected groups at 39 dpi (P = 0.021) only (Fig. 1D). The absolute
lymphocytes count globally decreased in both infected groups com-
pared with control, but TvMT1-infected animals exhibited peak lym-
phocyte levels between 3 and 18 dpi, whereas TvLIEM176-infected
animals exhibited lymphocyte counts steadily decreasing from the be-
ginning of the infection (Fig. 2A) until recovery at the very end of the
infection. In both cases, after 18 dpi there were statistical diﬀerences
between infected and control groups (P < 0.001).
Neutrophil, monocyte and eosinophil counts varied during the ex-
perimental period, but they always stayed within normal ranges for
sheep (Fig. 2B, 2C, 2D). Neutrophils had a slight but constant decrease
during the experimental period in TvLIEM176-infected animals. In
TvMT1-infected animals, neutrophils had a dramatic decrease until 9
dpi and then there was a slight recovery between 9 and 18 dpi, after
which levels remained stable until the end of the study. Neutrophil
counts were always lower in TvMT1- than in TvLIEM176- infected
animals (Fig. 2B).
Monocyte counts were higher in TvLIEM176-infected animals
compared with the TvMT1-infected and control groups, with compar-
able ﬂuctuations during the experimental period. In TvMT1-infected
animals, monocytes had a peak between 12 and 18 dpi and then, they
had a similar proﬁle than in the animals from the control group.
Globally, monocytes counts were always greater in TvLIEM176 group
than those in TvMT1 group (Fig. 2C).
Eosinophil levels in TvMT1-infected and control animals were si-
milar, with low numbers of circulating eosinophils. Conversely, animals
infected with TvLIEM176 had a signiﬁcant increase of eosinophils be-
tween 6 and 36 dpi compared with control and TvMT1 groups, and
eosinophil levels were higher in TvLIEM176- than in TvMT1- infected
animals during the complete experimental period (Fig. 2D).
Broadly, TvLIEM176 strain induced a less severe anemia compared
with TvMT1. This is similar to the relatively milder phenotype of the
WBC analyses in composite for TvLIEM176: TvLIEM176 induced a
lower decrease in WBC, mainly a lower decrease in neutrophils, higher
decrease in lymphocytes, and increase in monocytes and eosinophils
compared with TvMT1. The complete hematological data are presented
in the Table S3, Figs. S1 and S2.
Vital signs (body temperature, heart rate, and respiratory rate) of
sheep infected with both T. vivax isolates were recorded throughout the
experiment (Fig. 3). The mean body temperatures of infected groups
(39.6 °C [95% CI, 39.3 °C–39.9 °C], 39.3 °C [95% CI, 39.0 °C–39.6 °C])
for TvMT1 and TvLIEM176, respectively) were slightly higher than that
of the control group (39.0 °C [95% CI, 38.7 °C–39.3 °C]). The body
temperature of infected animals started rising from 6 dpi, coincident
with the ﬁrst peak of parasitemia, and then ﬂuctuated throughout the
study period (Fig. 3A). The highest mean body temperature recorded
was 40.0 °C (95% CI, 39.7 °C–40.3 °C) from the TvMT1-infected ani-
mals at 6 and 24 dpi. Signiﬁcant statistical diﬀerences were found be-
tween control non-infected group and the TvMT1 group from 6 to 24
dpi (P < 0.001) and on 39 (P = 0.012), 48 (P < 0.001), 51
(P < 0.001), 57 (P < 0.001), and 60 (P < 0.001) dpi. TvLIEM176-
infected animals only had fever peaks on 6, 9 and 57 dpi (Fig. 3A).
The mean baseline heart rate of the three groups of animals was
similar at day 0 pre-inoculation (Control: 63.3 [95% CI, 56.5–70.1]
beats/min, TvMT1-inoculated: 70.3 [95% CI, 63.5–77.1] beats/min,
TvLIEM176-infected: 66.3 [95% CI, 59.5–73.1] beats/min). In the an-
imals inoculated with TvMT1 isolate, the heart rate began to increase
by day 3 following infection (98.7 [95% CI, 91.9–105.5] beats/min),
reached the highest values (104 [95% CI, 97.2–110.8] beats/min) at 21
dpi and then had the tendency to keep stable around 90 beats/min
during the rest of the study. TvLIEM176-infected animals showed a
delayed and less marked increase of their heart rate from 6 dpi, and
their average highest value (96 [95% CI, 89.2–102.8] beats/min at 9
and 18 dpi) was not as high as that in TvMT1-infected animals (Fig. 3B).
The heart rate changes recorded in both infected groups were sig-
niﬁcantly higher (P <0.001 ) than those observed in the non-infected
group. There were statistically signiﬁcant heart rate diﬀerences on 3
(P < 0.001), 6 (P = 0.004), 12 (P < 0.001), 21–33 (P < 0.001), 57
(P = 0.023) and 60 (P = 0.047) dpi between both infected groups
(Fig. 3B).
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Respiratory rates followed a similar pattern (Fig. 3C). There was a
fast increase of respiratory rate in TvMT1-infected animals from around
20 to 41 breaths/min during the ﬁrst six days of infection, oscillating
between 33 to 42 breaths/min until 39 dpi. Then, there was a decrease
to about 30 breaths/min until the end of the study. In TvLIEM176-in-
fected group, the increase in respiratory rate was slower, reaching 45
breaths/min at 18 dpi. A persistent decrease to around 29–30 breaths/
min occurred from 30 dpi (Fig. 3C). Complete vital signs data are
presented in the Table S3 and Fig. S3.
The clinical outcome of the disease was characterized by a variety of
clinical signs. Initially, reduced feed intake and lethargy were observed.
Later, facial edema, enlarged superﬁcial lymph nodes, unilateral and
bilateral lacrimation, pale or icteric membrane mucous, and weight loss
were also observed. More severe clinical signs (icteric membrane mu-
cous and harsh emaciation) were observed in the three TvMT1-infected
animals.
3.2. T. vivax strains with diﬀerent virulence and pathogenicity patterns
exhibit diﬀerential expression of some proteins
After separating sample-speciﬁc labeled proteins by DIGE as de-
scribed in Materials and Methods Sections 2.6 and 2.7, 754 spots were
detected by SameSpots software in the DIGE gel images from T. vivax
TvLIEM176 and TvMT1 strains. Spot intensity levels were quantitated
and normalized using a Cy2-labeled internal standard. Seventeen pro-
tein spots which had at least a 2-fold higher intensity (ANOVA
P < 0.05, Power> 0.9) in T. vivax, compared with T. evansi, were
initially identiﬁed. These 17 T. vivax-speciﬁc spots were then analyzed
to identify those with at least a 2-fold diﬀerence in intensity (ANOVA
P < 0.05, Power> 0.9) between the T. vivax strains (Fig. 4). Six spots
exhibited higher intensity in TvMT1 (758, 793, 1912, 1909, 1903, and
1906), and four in TvLIEM176 (1919, 1979, 1986, and 559). The rest of
the spots (1552, 1099, 985, 602, 845, 1928, and 1969) were equally
intense in both T. vivax strains. All 17 spots selected in the ﬁrst
screening (T. vivax-speciﬁc) were excised and analyzed by MS/MS. No
spectra were recovered from one TvMT1 high-intensity spot (1909) but
the spectra from the remaining 16 spots were analyzed: ﬁve more in-
tense in TvMT1, four in TvLIEM176, and seven with similar intensity in
both strains.
Among these 16 spots, 29 peptides were consistent with proteins in
the Uniprot database. These peptides were used to BLAST the T. vivax
transcriptome database (Greif et al., 2013). Six proteins were identiﬁed
from the spots displaying higher intensity in TvLIEM176, putatively
annotated as alpha tubulin, beta tubulin, arginine kinase, glucose-
regulated protein 78, paraﬂagellar protein 3, and T-complex protein 1
subunit theta. Eight proteins were identiﬁed from the spots displaying
higher intensity in TvMT1, putatively annotated as heat shock protein
70 (HSP70), chaperonin HSP60, T-complex protein 1 subunit alpha,
pyruvate kinase, glycerol kinase, inosine-5'-monophosphate dehy-
drogenase, 73 kDa paraﬂagellar rod protein, and vacuolar ATP synthase
(Table 1). Proteins upregulated in TvLIEM176 strain are potentially
associated with higher virulence but lower pathogenicity, and proteins
upregulated in TvMT1 strain with higher pathogenicity but lower
virulence. These proteins recovered from spots of strain-speciﬁc in-
tensity were also classiﬁed according to their properties as vaccine
candidates, potential drug targets and diagnosis candidates given the
ontological assignment already described in the literature (Table 1).
Mass spectrometry results evidenced several protein chains for a
given identiﬁcation (TvMiraNov_c43: spots 1979, 1919, 1986;
TvMiraNov_rep_c5263: spots 1979, 1919, 1986; TvMiraNov_c5617:
Fig. 1. Hematological analysis of non-infected and experimentally-infected sheep with Trypanosoma vivax strains TvMT1 and TvLIEM176. Adjusted mean values and
95% conﬁdence intervals of parasitemia (log10 parasites/ml, panel A), PCV (%, panel B), hemoglobin (g/dl, panel C), and WBC counts (cells x 103/μl, panel D) during
infection. Each group consisted of three sheep.
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spots 758, 1912; TvMiraNov_c959: spots 1903, 1906).
4. Discussion
Proteomic tools are useful for probing host-parasite crosstalk.
Theoretically and empirically, both genotypic and phenotypic diﬀer-
ences between trypanosomes strains are likely associated with the
disease outcome. In this study, it was used a natural model of infection
(sheep) to study the diﬀerent patterns of virulence and pathogenicity of
two T. vivax strains and to identify proteins whose potential for strain-
speciﬁc diﬀerential expression could be inﬂuencers of clinical features
of infection by that strain.
Diﬀerences in the severity and progression of trypanosome-caused
diseases (virulence and pathogenicity, as deﬁned in this study) have
been described for infections of T. bruceigambiense (Holzmuller et al.,
2008; Kaboré et al., 2018), T. bruceirhodesiense (Maclean et al., 2007;
Muchiri et al., 2015), T. congolense(Bengaly et al., 2002a, 2002b;
Grébaut et al., 2009; Masumu et al., 2006), T. evansi (Perrone et al.,
2018; Verdillo et al., 2012) and T. cruzi (Andrade et al., 1985; Belew
et al., 2017; Henrique et al., 2016; Lauria-Pires and Teixeira, 1996).
Similarly, diﬀerences in virulence and pathogenicity have been re-
cognized between East and West African strains of T. vivax, the West
African strains being generally more pathogenic to cattle (Gardiner,
1989). However, Latin American T. vivax infections are considered
generally chronic and mild, with rare outbreaks of severe disease
(Osório et al., 2008). This is the ﬁrst study comparing the diﬀerent
virulence and pathogenicity patterns of two Venezuelan T. vivax strains
isolated in animals. It was found that they exhibit diﬀerences in the
severity of their disease proﬁles and diﬀerences in their expressed
proteomes.
The clinical outcome in sheep infected with both strains was a three-
phase disease pattern. The prepatent period between the parasite in-
oculation and the appearance of trypanosomes in blood was three days,
and the animals remained asymptomatic during this time. Then, an
acute period was observed, characterized by high, persistent, and
ﬂuctuating parasitemia, recurrent fever, a severe decrease of PCV, and
several pathophysiological and clinical signs. Finally, animals devel-
oped sub-acute disease with lower and ﬂuctuating parasitemia. In spite
of gradual cessation of disease symptoms, PCV values remained low
during the sub-acute phase. The same disease pattern in sheep was
observed using other T. vivax isolates (Anosa and Isoun, 1980; Maikaje
et al., 1991; Valera et al., 2005).
However, substantial strain-speciﬁc diﬀerences in parasitemia,
clinical signs, and hematological parameters in T. vivax infections were
observed. Animals infected with TvMT1 strain showed lower values of
parasitemia when compared with TvLIEM176-infected animals,
whereas the induced clinical signs were more severe in TvMT1 infec-
tions than in TvLIEM176 ones. Similarly, the consistent higher para-
sitemia observed with the TvLIEM176 strain was associated with a
lower magnitude of global decrease in WBC. Speciﬁcally, in
TvLIEM176-infected sheep, neutrophil decrease was less severe, yet
lymphocyte decrease was more severe, and levels of monocytes and
eosinophils were higher than in those in TvMT1 infected sheep. Such
diﬀerences in immune cell populations between animals infected with
each strain likely reﬂect some divergence in modulation of the host
immune response to these strains. Such strain-speciﬁc eﬀects have been
well detailed in bovine trypanosomosis caused by T. congolense(Taylor,
1998; Taylor and Mertens, 1999) and to a lesser extent in mouse in-
fections with T. vivax (Blom-Potar et al., 2010; Morrison et al., 2010).
Anemia became marked particularly in animals infected with the
Fig. 2. Adjusted mean absolute values and 95% conﬁdence intervals for blood concentrations of lymphocytes (cells x 103/μl, panel A), neutrophils (cells x 103/μl,
panel B), monocytes (cells x 102/μl, panel C), and eosinophils (cells x 103/μl, panel D) of non-infected and experimentally-infected sheep with Trypanosoma vivax
strains TvMT1 and TvLIEM176. Each group consisted of three sheep.
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TvMT1 strain as the disease progressed. PCV decrease, and the con-
sequent anemia, is the hallmark of T. vivax pathogenesis and is used as
one of the main disease indicators (Osório et al., 2008). The mechan-
isms that generate anemia in trypanosomosis have not been totally
elucidated and the pathogenesis of this feature is extremely complex
and multifactorial. A number of factors have been incriminated in the
etiology of anemia and these include hemolysis as a result of im-
munological factors and trypanosome products, hemodilution and
Fig. 3. Vital signs of non-infected and experimentally-infected sheep with Trypanosoma vivax strains TvMT1 and TvLIEM176. Adjusted mean values and 95%
conﬁdence intervals of body temperature (°C, panel A), heart rate (beats/min, panel B), and respiratory rate (breaths/min, panel C) during infection. Each group
consisted of three sheep.
Fig. 4. Two-dimensional synthetic image of diﬀerential in-gel electrophoresis gels displaying diﬀerentially expressed protein spots identiﬁed in the proteome of
Trypanosoma vivax TvMT1 and TvLIEM176 strains.
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impaired erythropoiesis (Katunguka-Rwakishaya et al., 1992). In in-
fections with T. vivax, direct alteration of the red blood cells surface is
expected to be an important mechanism in anemia pathogenesis due to
the secretion of sialidases by these parasites, leading to their phago-
cytosis (Guegan et al., 2013). Overall, data collected from sheep in-
fections demonstrated that TvLIEM176 strain had high virulence and
moderate pathogenicity and TvMT1 strain had low virulence and high
pathogenicity.
These striking diﬀerences led to the hypothesis that these two
strains also diﬀerentially express their proteome when replicating in
sheep. The spots in DIGE analysis that were particularly abundant in the
T. vivax strains relative to their intensity in T. evansi, a diﬀerent try-
panosome species, were identiﬁed. However, we focused only on the
diﬀerentially expressed proteins between both T. vivax strains. MS/MS
spectra of these spots resulted in the identiﬁcation of 29 proteins, of
which 14 were found within spots that were diﬀerentially expressed
between the high virulence/moderate pathogenicity and the low viru-
lence/high pathogenicity T. vivax strains. Trypanosomes have acquired
eﬃcient immune evasion mechanisms to undermine protective host
immune response and survive in the host’s extracellular environment
(Stijlemans et al., 2017). Factors produced by the parasites would be
necessary for this, and diﬀerences in expression of these factors could
play a role in disease pathogenicity (Siqueira-Neto et al., 2018;
Stijlemans et al., 2017; Taylor, 1998).
Proteins from DIGE spots that are more intense in the more virulent
strain (TvLIEM176) were the tubulins (alpha and beta chains), which
are a fundamental component of microtubules. The highly conserved
eukaryotic tubulins are vital to cell division, motility, intracellular
transport, and signal transduction (Lama et al., 2012). Despite tubulin
sequence conservation (Werbovetz et al., 2003), there are diﬀerences in
orthologue susceptibility to antimitotic agents, likely reﬂecting struc-
tural diﬀerences among species (Bobba et al., 2017; Lama et al., 2012;
Werbovetz et al., 2003). The stable biological characteristics of trypa-
nosome tubulin make it an ideal potential drug target and also a pro-
spective vaccine candidate (Kurup and Tewari, 2012; Lama et al., 2012;
Li et al., 2007; Nanavaty et al., 2016; Werbovetz, 2002). As tubulin
peptides were identiﬁed in multiple spots, proteoforms varying in
molecular weight and isoelectric point are likely, possibly corre-
sponding to diﬀerent maturation states and/or post-translational
modiﬁcations. Diﬀerent tubulin proteoforms might vary in function-
ality (Sasse and Gull, 1988), aﬀecting progression through the trypa-
nosome cell cycle, and thus virulence. Moreover, diﬀerent secreted
proteoforms of tubulin alpha and beta chains of T. congolensehave been
reported as virulence factors (Grébaut et al., 2009). The importance of
microtubules in intracellular transport (Montalvão et al., 2018) could
also explain the likely higher expression of tubulin in the TvLIEM176
strain.
Another family of proteins related to parasite motility are the par-
aﬂagellar rod (PFR) proteins. Here, it was found a putative 73 kDa
paraﬂagellar rod protein in DIGE spots of higher intensity in the strain
exhibiting higher pathogenicity and a paraﬂagellar protein 3 homo-
logue in higher intensity spots of the more virulent strain. The PFR, a
unique attribute of kinetoplastids, is essential for motility and cell
viability (Koyfman et al., 2011; Portman and Gull, 2010; Ralston and
Hill, 2008). PFR proteins are considered potential drug targets and
excellent vaccines candidates due to their high sequence conservation
between kinetoplastid parasites and lack of human and livestock animal
near orthologues (Abdille et al., 2008; Clark et al., 2005; Morell et al.,
2006). Their potential as vaccine candidates has been demonstrated by
immunization of hamsters with Leishmania mexicana PFR2 which re-
sulted in delayed appearance of cutaneous lesions and signiﬁcant re-
ductions in lesion size (Saravia et al., 2005).
Two putative heat shock protein homologues were identiﬁed in
DIGE spots that were more intense in the more pathogenic strain
(TvMT1): HSP60 and HSP70. Conversely, the putative glucose-regu-
lated protein 78 (GRP78), a member of the HSP70 family localized in
endoplasmic reticulum, was found in the spots of higher intensity in the
less pathogenic but more virulent strain (TvLIEM176). The heat shock
proteins (HSPs) inﬂuence folding, assembly, intracellular localization,
secretion, regulation and degradation of other proteins (Folgueira and
Requena, 2007). In trypanosomatids, links between HSP70 and devel-
opment and survival of parasites during temperature changes have been
established (Folgueira and Requena, 2007; Louw et al., 2010). Also,
HSPs are highly immunogenic and although they are very similar to
their human and animal homologs, they possess many determinants
that induce strong humoral and cellular immune responses during in-
fection (Bossard et al., 2010; Krautz et al., 1998). Given their complex
roles in disease presentation though, it would be diﬃcult to deﬁne them
precisely as drug targets (Evans et al., 2010).
Another diﬀerentially expressed protein in this study was the T.
vivax homologue of the glycolytic enzyme pyruvate kinase (PK), which
was more expressed by the TvMT1 strain. PK activity is relatively high
in the T. brucei cytosol and is crucial for carbohydrate and energy
metabolism (Ernest et al., 1998); therefore, it has been considered as a
potential drug target. Pharmacological inhibition or RNAi silencing of
this enzyme causes ATP depletion, cell growth arrest, and parasite
death (Albert et al., 2005; Coustou et al., 2003; Worku et al., 2015).
Additionally, the antigenic properties of PK in T. evansi and T. con-
golenseare known (Pinto Torres et al., 2018; Yadav et al., 2017), and PK
has been identiﬁed as a diagnostic biomarker in T. congolense (Pinto
Torres et al., 2018).
This study highlights the variation in protein expression between T.
vivax strains of diﬀerent geographical origins. The strains compared
here were from very distant Venezuelan locations and environments. It
is also showed diﬀerences in disease outcomes of these strains. It is
possible but not proven that the molecular plasticity related to the
diﬀerences in these two T. vivax strains is responsible for their diﬀer-
ences in virulence and pathogenicity. For this study, the two available
Venezuelan strains with the highest known pathogenicity and virulence
were selected, but it might be possible to ﬁnd additional diﬀerences in
protein expression with strains from other regions. It is also important
to consider host variability in susceptibility to infection, which was not
considered here. Nevertheless, these results provide circumstantial
evidence for varying virulence and pathogenicity patterns inﬂuenced by
parasite genetic diversity or molecular plasticity.
Further studies are needed to establish a causal relationship be-
tween disease outcome and protein expression in T. vivax infections.
Finally, additional studies are to validate the biological properties of
the proteins identiﬁed here in order to consider their use in prevention,
identiﬁcation, or treatment of South American animal trypanosomosis
caused by T. vivax.
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